|
注册号: Registration number: |
ChiCTR2500105319 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-02 08:09:21 |
|
注册时间: Date of Registration: |
2025-07-02 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
解剖性肝切除术中三维可视化技术的应用与效果评估研究 |
|
Public title: |
Application and Effect Evaluation Study of Three-Dimensional Visualization Technology in Anatomical Liver Resection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
解剖性肝切除术中三维可视化技术的应用与效果评估研究 |
|
Scientific title: |
Application and Effect Evaluation Study of Three-Dimensional Visualization Technology in Anatomical Liver Resection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李志杰 |
研究负责人: |
李志杰 |
|
Applicant: |
Zhijie Li |
Study leader: |
Zhijie Li |
|
申请注册联系人电话: Applicant telephone: |
+86 10 6693 3487 |
研究负责人电话:
Study leader's |
+86 10 6693 3487 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jjtony10@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jjtony10@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区西四环中路100号 |
研究负责人通讯地址: |
北京市丰台区西四环中路100号 |
|
Applicant address: |
No. 100, West Fourth Ring Middle Road, Fengtai District, Beijing |
Study leader's address: |
No. 100, West Fourth Ring Middle Road, Fengtai District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院第五医学中心 |
||
|
Applicant's institution: |
The Fifth Medical Center of the Chinese People's Liberation Army General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院第五医学中心 |
||
|
Affiliation of the Leader: |
The Fifth Medical Center of the Chinese People's Liberation Army General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2024-7-116-1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-25 00:00:00 | ||
|
伦理委员会联系人: |
孙滢滢 |
||
|
Contact Name of the ethic committee: |
Yingying Sun |
||
|
伦理委员会联系地址: |
北京市丰台区东大街8号 |
||
|
Contact Address of the ethic committee: |
8 Dongdajie, Fengtai District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6694 7798 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院第五医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The Fifth Medical Center of the Chinese People's Liberation Army General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区西四环中路100号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 100, West Fourth Ring Middle Road, Fengtai District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
肝脏肿瘤(如肝癌)、肝内胆管结石、肝脏良性占位性病变 |
||||||||||||||||||||||
|
Target disease: |
Liver tumors (such as hepatocellular carcinoma), intrahepatic bile duct stones, benign focal liver lesions |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
1.评估三维可视化技术在解剖性肝切除术中的可行性:研究目的可能是验证三维可视化技术是否适用于解剖性肝切除术,并评估其在手术过程中提供解剖信息的准确性和可靠性。 2.评估三维可视化技术对手术过程的辅助作用:研究可能旨在探讨三维可视化技术在解剖性肝切除术中对外科医生的手术规划和操作的辅助作用。这包括评估该技术对手术时间、手术切除范围的确定以及手术操作的精确性和安全性的影响。 3.比较三维可视化技术与传统二维影像的效果:研究可能旨在比较使用三维可视化技术和传统二维影像进行解剖性肝切除术的效果差异。这可能涉及术前手术规划的准确性、手术切除范围的确定、手术时间和并发症发生率等指标的比较。 4.评估三维可视化技术对患者术后预后的影响:研究可能关注使用三维可视化技术进行解剖性肝切除术对患者术后预后的影响。这包括评估手术切除范围的准确性对肿瘤复发率和生存率的影响,以及术后并发症的发生率等。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.Evaluating the feasibility of three-dimensional visualization technology in anatomical liver resection surgery: The research objective may be to verify the applicability of three-dimensional visualization technology in anatomical liver resection surgery and assess its accuracy and reliability in providing anatomical information during the surgical process. 2.Assessing the adjunctive role of three-dimensional visualization technology in the surgical process: The study may aim to explore the adjunctive role of three-dimensional visualization technology for surgical planning and operation in anatomical liver resection surgery. This includes evaluating the impact of this technology on surgical time, determination of the extent of surgical resection, and the precision and safety of surgical procedures. 3.Comparing the effects of three-dimensional visualization technology with traditional two-dimensional imaging: The research may aim to compare the differences in outcomes between using three-dimensional visualization technology and traditional two-dimensional imaging for anatomical liver resection surgery. This comparison may involve assessing the accuracy of preoperative surgical planning, determination of the extent of surgical resection, surgical time, and the incidence of complications. 4.Assessing the impact of three-dimensional visualization technology on postoperative prognosis of patients: The study may focus on the impact of using three-dimensional visualization technology for anatomical liver resection surgery on the postoperative prognosis of patients. This includes evaluating the effect of the accuracy of surgical resection extent on tumor recurrence rate and survival rate, as well as the incidence of postoperative complications. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.存在严重的心脏病、肺病或其他系统性疾病,不适合手术干预的患者 2.存在严重的肝功能不全 3.接受过其他影响手术切除范围的治疗干预 4.影像学检查质量不足,无法进行准确的三维可视化技术应用 5.存在活动性感染或严重免疫功能障碍的患者 6.存在精神疾病或认知功能障碍的患者,无法理解和遵守研究要求 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with severe heart disease, lung disease, or other systemic illnesses that make them unsuitable for surgical intervention. 2.Patients with severe liver dysfunction. 3.Patients who have undergone other therapeutic interventions that may affect the extent of surgical resection. 4.Poor quality of imaging examinations, making accurate application of three-dimensional visualization technology not feasible. 5.Patients with active infections or severe immunodeficiency. 6.Patients with mental illness or cognitive impairments who cannot understand and comply with the study requirements. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-12 00:00:00至 To 2027-05-12 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-08-06 00:00:00 至 To 2027-05-12 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开原始数据日期: 2027年12月31日,公开方式: 通过网络平台公开,网络平台名称:Research Data Repository,网址: www.researchdatarepository.com |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Date of disclosure of original data: December 31, 2027, Disclosure method: Disclosure through the online platform, online platform name: Research Data Repository, website: www.researchdatarepository.com |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表涵盖患者基本信息,如姓名、年龄、性别等。疾病详情包括诊断、症状、病史。术前记录三维可视化数据(重建时间、软件设备、肝脏结构描述)与手术规划。术中记录实际操作情况,如是否依规划手术、手术时间、出血量、突发问题。术后记录恢复状况(住院时长、并发症、处理措施)、病理结果及长期随访情况(肝功能指标、影像学复查结果等)。 电子采集和管理系统选用医院电子病历或专用研究数据管理系统,培训录入人员。保障数据安全,存储加密,设用户权限,定期本地与云端备份。严控数据质量,录入时设逻辑检查与必填提示,定期审核,异常或缺失数据及时与原始病历核对纠正。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The case report form covers basic patient information such as name, age, gender, etc. Disease details include diagnosis, symptoms, and medical history. Preoperatively, record three-dimensional visualization data (reconstruction time, software used, description of liver structure) and surgical planning. Intraoperatively, document actual surgical procedures, including adherence to the surgical plan, surgical time, blood loss, and any unforeseen issues. Postoperatively, record recovery status (length of hospital stay, complications, management), pathological results, and long-term follow-up information (liver function indicators, imaging re-examination results, etc.). An electronic data collection and management system may involve using the hospital's electronic medical records or a dedicated research data management system, along with training for data entry personnel. Ensure data security by encrypting storage, setting user permissions, and regularly backing up data locally and on the cloud. Strictly control data quality by implementing logic checks and mandatory prompts during data entry, conducting regular audits, and promptly verifying and correcting any abnormal or missing data against the original medical records. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |